HK1047698A1 - 用以治療細胞增生失調的病毒 - Google Patents

用以治療細胞增生失調的病毒

Info

Publication number
HK1047698A1
HK1047698A1 HK02108779.8A HK02108779A HK1047698A1 HK 1047698 A1 HK1047698 A1 HK 1047698A1 HK 02108779 A HK02108779 A HK 02108779A HK 1047698 A1 HK1047698 A1 HK 1047698A1
Authority
HK
Hong Kong
Prior art keywords
viruses
treatment
proliferative disorders
cellular proliferative
cellular
Prior art date
Application number
HK02108779.8A
Other languages
English (en)
Inventor
C Coffey Matthew
G Thompson Bradley
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of HK1047698A1 publication Critical patent/HK1047698A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK02108779.8A 1999-11-12 2002-12-03 用以治療細胞增生失調的病毒 HK1047698A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16487899P 1999-11-12 1999-11-12
PCT/CA2000/001329 WO2001035970A1 (en) 1999-11-12 2000-11-08 Viruses for the treatment of cellular proliferative disorders

Publications (1)

Publication Number Publication Date
HK1047698A1 true HK1047698A1 (zh) 2003-03-07

Family

ID=22596481

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02108779.8A HK1047698A1 (zh) 1999-11-12 2002-12-03 用以治療細胞增生失調的病毒

Country Status (11)

Country Link
US (9) US6596268B1 (zh)
EP (2) EP1955703A1 (zh)
JP (1) JP2003514024A (zh)
AU (1) AU782020B2 (zh)
BR (1) BR0015491A (zh)
CA (2) CA2720361A1 (zh)
HK (1) HK1047698A1 (zh)
MX (1) MXPA02004736A (zh)
NZ (1) NZ518454A (zh)
WO (1) WO2001035970A1 (zh)
ZA (1) ZA200203041B (zh)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
CA2720361A1 (en) 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
CA2382998A1 (en) * 1999-12-08 2001-06-14 Onyx Pharmaceuticals, Inc. Mutant simplex virus for treating unwanted hyperproliferative cell growth
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
AR028040A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US20020147996A1 (en) * 2000-07-07 2002-10-10 Benjamin Thomas L. Diagnosing and treating cancer cells using Sal2
US20030157481A1 (en) * 2001-12-10 2003-08-21 Benjamin Thomas L. Diagnosing and treating cancer cells using T-HR mutants and their targets
US20020156039A1 (en) * 2000-07-07 2002-10-24 Benjamin Thomas L. Diagnosing and treating cancer cells using Sal2
US20050013803A1 (en) * 2000-07-07 2005-01-20 Benjamin Thomas L. Diagnosing and treating cancer cells using mutant viruses
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
AU2002353031A1 (en) * 2001-12-07 2003-06-23 Bayer Corporation Use of parapox b2l protein to treat cancer and modify immune responses
EP1605053A1 (en) 2002-03-26 2005-12-14 Oncolytics Biotech Inc. Use of adenoviruses mutated in the VA genes for cancer treatment
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
AU2003223686A1 (en) * 2002-04-26 2003-11-10 Wellstat Biologics Corporation Immunogenic agent therapy using plasmapheresis or exchange transfusion
AU2003249059A1 (en) 2002-07-24 2004-02-09 Arizona Board Of Regents Use of vaccinia virus deleted for the e3l gene as a vaccine vector
KR20120002613A (ko) 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
CN100562570C (zh) 2003-06-18 2009-11-25 吉恩勒克斯公司 修饰的重组痘苗病毒及其它微生物,及其应用
EP1648233A4 (en) * 2003-07-08 2006-08-23 Univ Arizona VACCINE VACCINE MUTANTS INSTEAD OF ONCOLYTIC AGENTS
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2006031996A2 (en) * 2004-09-14 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeting viruses using a modified sindbis glycoprotein
WO2006071966A2 (en) * 2004-12-29 2006-07-06 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1
NZ556409A (en) 2005-02-23 2010-09-30 Bavarian Nordic As Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
NZ577283A (en) * 2005-03-07 2010-11-26 Robarts Res Inst Use of a Myxoma virus that does not express functional M135R
US20070004767A1 (en) * 2005-06-30 2007-01-04 Gutmann David H Methods for treating neurofibromatosis 1
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
JP2009507853A (ja) 2005-09-07 2009-02-26 ジェンネレックス インコーポレイティッド Ｇｍ−ｃｓｆ発現ポックスウイルスを用いる転移性および／または全身播種性癌の全身処置
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
EP1984007B1 (en) * 2006-02-13 2015-08-19 Oncolytics Biotech Inc. Use of low dose local immune suppression to enhance oncolytic viral therapy
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US20090117034A1 (en) 2007-06-15 2009-05-07 Nanhai Chen Microorganisms for imaging and/or treatment of tumors
US20090162288A1 (en) * 2007-07-18 2009-06-25 Nanhai Chen Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods
WO2009135614A2 (en) * 2008-05-09 2009-11-12 Bayer Schering Pharma Aktiengesellschaft Use of a virus regimen for the treatment of diseases
EP2300023A2 (en) * 2008-05-16 2011-03-30 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
EP2296678A4 (en) * 2008-05-27 2012-03-21 Oncolytics Biotech Inc MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION
US20120064143A1 (en) 2008-11-11 2012-03-15 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
ES2671570T3 (es) 2009-09-14 2018-06-07 Sillajen Biotherapeutics, Inc. Terapia combinada contra el cáncer con virus oncolítico de vaccinia
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CA2824277C (en) 2011-01-04 2021-08-31 Jennerex, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
WO2012122649A1 (en) * 2011-03-15 2012-09-20 Ottawa Hospital Research Institute Recombinant orf virus
CA2836299A1 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
EP2764119A2 (en) 2011-10-05 2014-08-13 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
DE102013105144A1 (de) * 2013-05-17 2014-11-20 Arno Thaller Pharmazeutisches Kombinationspräparat mit einem anti-idiotypischen Antikörperfragment
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
EP3209382B1 (en) 2014-10-24 2020-11-25 Calidi Biotherapeutics, Inc. Combination immunotherapy approach for treatment of cancer
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
WO2016168862A1 (en) 2015-04-17 2016-10-20 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
US10105436B2 (en) 2015-08-11 2018-10-23 Calidi Biotherapeutics, Inc. Smallpox vaccine for cancer treatment
ES2831080T5 (es) 2016-01-08 2023-10-30 Replimune Ltd Virus oncolítico modificado
CN105754952B (zh) * 2016-02-16 2020-07-10 中国农业科学院兰州兽医研究所 抗羊痘病毒k3l蛋白c末端的单克隆抗体及其应用
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
MX2018010204A (es) 2016-02-25 2019-05-06 Memorial Sloan Kettering Cancer Center Virus de la vaccinia atenuada competentes para replicacion con la supresion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer.
CN109152827B (zh) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
KR20190007416A (ko) * 2016-03-25 2019-01-22 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 합성적으로 엔벨롭된 바이러스
WO2017205674A1 (en) * 2016-05-25 2017-11-30 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic vaccinia virus mutants and using same for cancer treatment
AU2017299983B2 (en) 2016-07-21 2021-01-07 Kolon Life Science, Inc. Recombinant vaccinia virus and use thereof
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
US10610583B2 (en) 2017-08-31 2020-04-07 Regents Of The University Of Minnesota Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
BR112020014727A2 (pt) * 2018-01-19 2020-12-08 Kolon Life Science, Inc. Vírus vaccinia recombinante e composição farmacêutica compreendendo o mesmo
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
CA2234060A1 (en) 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
CA2250041A1 (en) * 1996-03-29 1997-10-09 University Of Otago Parapoxvirus vectors
EP0977595A4 (en) 1996-05-31 2001-05-16 Genetic Therapy Inc PREVENTION OF GAS REACTION AGAINST HOST USING THYMO-DEPENDENT LYMPHOCYTES CONTAINING POLYNUCLEOTIDES ENCODING NEGATIVE SELECTION MARKERS
JPH1087503A (ja) 1996-09-06 1998-04-07 Nippon Chem Res Kk 神経系腫瘍細胞のアポトーシス剤
FR2759614B1 (fr) 1997-02-19 1999-03-19 Ind Regionale Batiment Element de construction obtenu par moulage
WO1998050063A1 (en) 1997-05-01 1998-11-12 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
GB9708918D0 (en) 1997-05-01 1997-06-25 Ppl Therapeutics Scotland Ltd Methods
AU7285098A (en) 1997-05-06 1998-11-27 Kemin Industries, Inc. Anti-fungal protein extracts from seeds of marigold
NZ500791A (en) * 1997-05-08 2002-10-25 Genetic Therapy Inc Gene transfer with adenoviruses having modified fiber proteins
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
AU9603898A (en) * 1997-10-09 1999-05-03 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP1061806A4 (en) * 1998-03-12 2001-09-12 Univ Pennsylvania PRODUCTIVE CELLS FOR REPLICATION-SELECTIVE VIRUSES FOR TREATING Vicious DISEASES
WO1999055910A1 (en) 1998-04-24 1999-11-04 Arizona Board Of Regents Method of inducing apoptosis in a target cell
US6245543B1 (en) 1998-06-22 2001-06-12 Richard Drake Mutated herpes simplex virus type 1 thymidine kinases and uses thereof
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6774119B1 (en) * 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
CA2720361A1 (en) * 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
EP1242116A2 (en) * 1999-12-22 2002-09-25 Onyx Pharmaceuticals, Inc. Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth

Also Published As

Publication number Publication date
US20080019980A1 (en) 2008-01-24
AU782020B2 (en) 2005-06-30
US20020028195A1 (en) 2002-03-07
EP1227828A1 (en) 2002-08-07
CA2388807A1 (en) 2001-05-25
CA2720361A1 (en) 2001-05-25
US20070086984A1 (en) 2007-04-19
US20120156168A1 (en) 2012-06-21
NZ518454A (en) 2004-07-30
US7582289B2 (en) 2009-09-01
WO2001035970A1 (en) 2001-05-25
US20080031886A1 (en) 2008-02-07
CA2388807C (en) 2013-08-06
MXPA02004736A (es) 2003-01-28
US8080241B2 (en) 2011-12-20
US7799329B2 (en) 2010-09-21
AU1262601A (en) 2001-05-30
US20100203147A1 (en) 2010-08-12
US6649157B2 (en) 2003-11-18
US20040057929A1 (en) 2004-03-25
EP1955703A1 (en) 2008-08-13
BR0015491A (pt) 2002-10-15
US20080019981A1 (en) 2008-01-24
US7964186B2 (en) 2011-06-21
US6596268B1 (en) 2003-07-22
US7252817B2 (en) 2007-08-07
US7731951B2 (en) 2010-06-08
ZA200203041B (en) 2003-12-09
JP2003514024A (ja) 2003-04-15
US8491886B2 (en) 2013-07-23

Similar Documents

Publication Publication Date Title
HK1047698A1 (zh) 用以治療細胞增生失調的病毒
IL144043A0 (en) Reovirus for the treatment of cellular proliferative disorders
HK1142833A1 (en) Methods for the treatment of cellular proliferative disorders
AU7621801A (en) Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
PL347942A1 (en) Device for the treatment of macular degeneration
IL143979A0 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
EP1274444A4 (en) DRUGS FOR THE TREATMENT OF PSYCHIATRICAL OR ABUSUS-RELATED DISORDER
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
HK1047588A1 (en) 2-Amino-4H-3,1-benzoxazine-4-one derivatives for the treatment of obesity
AU6910600A (en) Methods for the treatment of mental disorders
IL148579A0 (en) Oncolytic combinations for the treatment of cancer
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
HK1040184A1 (zh) 治療青光眼之組合療法
EP1207874A4 (en) METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES
HUP0200738A3 (en) Method of the treatment of incontinence
ZA200305230B (en) Methods to identify compounds useful for the treament of proliferative and differentiative disorders.
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
HK1059782A1 (en) Indole derivatives useful for the treatment of cnsdisorders
HRP20020262A2 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer
EP1210088A4 (en) 2-AMINOBENZOXAZINONE FOR TREATING THE HERPES SIMPLEX VIRUS
SI1220858T1 (en) Oxazinoquinolones useful for the treatment of viral infections
SI1147083T1 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
GB9816353D0 (en) The treatment of viral disorders
GB9816355D0 (en) The treatment of viral disorders

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)